The FDA has granted Glenmark Pharmaceuticals’ investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar of Novartis’s reference drug omalizumab (Xolair). The clinical trial will assess the pharmacokinetics of GBR 310 in comparison with Xolair in healthy adult volunteers between 18 and 65 years of age.
“GBR 310 has the potential to be among the first biosimilar candidates to be submitted for approval for a respiratory or allergic disease,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. GBR 310, a recombinant DNA-derived humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody, binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to a membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. The patents on the reference drug omalizumab will expire in the US on June 20, 2017, and in Europe in August 2017.
Omalizumab is indicated for the treatment of moderate to severe persistent asthma that is not controlled by inhaled steroids, and for chronic idiopathic urticaria not controlled by antihistamines. A majority of asthma patients are able to control the disease with long-acting beta agonists (eg, Advair, Symbicort), inhaled steroids, and rescue inhalers, which are the mainstay of asthma maintenance therapy. But some 5% to 15% of patients have severe asthma, and struggle to control the disease. They usually turn to injected biologicals including omalizumab and GlaxoSmithKline’s mepolizumab (Nucala) to reduce airway inflammation.
If GBR 310 advances through the biosimilar approval process, it has a potentially strong market position. Treatment options for patients with severe asthma are forecast to improve quite significantly, per market research firm GBI Research, with biologics in particular gaining prominence over the small-molecule therapeutics. The worldwide sales of omalizumab touched $755 million in 2015, and currently, about one-third of drugs in the asthma pipeline are biologics, GBI states. Procedures such as bronchial thermoplasty to treat asthma are still regarded by health insurance payers as experimental, with most refusing coverage for the procedure even though the costs of a 1-time treatment can be less than some newer biologics, and its success rate is similar to other approved treatments.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.